Overview

Bioequivalence Study of Clarithromycin 250mg Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
2003-11-01
Target enrollment:
Participant gender:
Summary
The objective of the study was to compare the single-dose oral bioavailability of Clarithromycin 250 mg tablets of Ranbaxy Laboratories with Biaxin 250 mg tablets of Abbott Laboratories in healthy, adult, human subjects under fasting conditions
Phase:
Phase 1
Details
Lead Sponsor:
Ranbaxy Laboratories Limited
Treatments:
Clarithromycin